Cargando…
Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants
BACKGROUND: Antibody–drug conjugates (ADC), such as enfortumab vedotin (EV), sacituzumab govitecan (SG), and RC-48, have shown outstanding response rates to local advanced or metastatic urothelial carcinoma (UC). However, their corresponding target expression characteristics in UC and its histologic...
Autores principales: | Fan, Yu, Li, Qinhan, Shen, Qi, Liu, Zhifu, Zhang, Zhenan, Hu, Shuai, Yu, Wei, He, Zhisong, He, Qun, Zhang, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063095/ https://www.ncbi.nlm.nih.gov/pubmed/35515131 http://dx.doi.org/10.3389/fonc.2022.858865 |
Ejemplares similares
-
Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022) -
TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma
por: Toda, Soji, et al.
Publicado: (2022) -
Nectin-4 is widely expressed in head and neck squamous cell carcinoma
por: Sanders, Christine, et al.
Publicado: (2022) -
Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021) -
Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer
por: Abbas, Mahmoud, et al.
Publicado: (2023)